NEW YORK (
CHANGE IN RATINGS
downgraded at Deutsche Bank to Hold from Buy. Price target lowered to $35 from $38. 2010 EPS estimates lowered to $2.44 from $2.48.
( KFT) reinstated at Credit Suisse with an Outperform rating and $35 price target. Upward momentum in operating margins. 2010 and 2011 EPS estimates set at $2.15 and $2.45, respectively.
( PALM) downgraded at BofA/Merrill to Underperform from Buy on increased competition. Price target cut in half to $10. Estimates lowered through 2011.
STOCK COMMENTS / EPS CHANGES
Brocade Communications Systems
price target cut at Goldman to $9 from $10.50. Disappointing Jan-quarter, but we see solid value in Brocade shares. Maintain Buy rating.
target, estimates lowered at Goldman. CPB price target trimmed by $2 to $36. 2011 and 2012 EPS estimates dropped to $2.66 and $2.88, respectively. Stock likely range-bound. Neutral rating.
Echo Global Logistics
target, estimates lower at Credit Suisse. ECHO price target cut to $17 from $20. Business mix causes shortfall in gross margins. Estimates slashed through 2012. Maintain Outperform rating.
target, estimates boosted at Goldman. ENDP price target raised to $24 from $22.50 on strong 2010. Estimates raised through 2013. Maintain Neutral rating.
price target cut at Citi to $106 from $110 after analysis of capital spending. 2011 EPS estimate raised to $3.42. Maintain Hold rating.
target, estimates boosted at BofA/Merrill. JWN price target improved by $2 to $40 as 4Q09 results beat expectations. 2011 and 2012 EPS estimates increased to $2.48 and $2.99, respectively. Neutral rating.
target, estimates improved at Goldman. LOW price target raised to $26. Lowe's 4Q09 results reinforced that momentum is improving. 2010 and 2011 EPS estimates lifted to $1.44 and $1.70, 2012 introduced at $1.95. Maintain Neutral rating.
Oil State International
target, estimates increased at Goldman. OIS price target raised by $2 to $49. Execution remain solid and early-cycle outlook improving. Estimates raised through 2012. Maintain Neutral rating.
target, estimate tweaked at Citi. TTEC price target raised to $21 from $19. 2010 EPS estimates lowered to $1.26. Good operating margins, poor cash flow. Reiterate Hold.
target, estimates raised at Credit Suisse. TXRH price target raised by a dollar to $16 after strong 4Q09 results. 2010 and 2011 EPS estimates lifted to 79 cents and 88 cents, respectively. Maintain Outperform rating.
estimates boosted at Credit Suisse. XLNX estimates raised through 2012 after a positive analysts day. Discussed target model which indicates upside growth. Maintain Neutral rating and $25 price target.
target increased, estimates lowered at Goldman. XNPT price target raised by a dollar to $9. Positive data from pancreatic cancer drug but regulatory path remains uncertain. Estimates lowered through 2012. Maintain Neutral rating.
This article was written by a staff member of TheStreet.com.